NCT01826422 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Cruz Guzmán Odel R, Chávez García AL, Rodríguez-Cruz M
Muscular dystrophies at different ages: metabolic and endocrine alterations. Int J Endocrinol. 2012;2012:485376. doi: 10.1155/2012/485376. Epub 2012 Jun 3.
Rodríguez-Cruz M, Cruz-Guzmán ODR, Almeida-Becerril T, Solís-Serna AD, Atilano-Miguel S, Sánchez-González JR, Barbosa-Cortés L, Ruíz-Cruz ED, Huicochea JC, Cárdenas-Conejo A, Escobar-Cedillo RE, Yam-Ontiveros CA, Ricárdez-Marcial EF
Potential therapeutic
Rodríguez-Cruz M, Sanchez R, Escobar RE, Cruz-Guzmán Odel R, López-Alarcón M, Bernabe García M, Coral-Vázquez R, Matute G, Velázquez Wong AC
Evidence of Insulin Resistance and Other Metabolic Alterations in Boys with Duchenne or Becker Muscular Dystrophy. Int J Endocrinol. 2015;2015:867273. doi: 10.1155/2015/867273. Epub 2015 May 19.

Effect of Eicosapentaenoic Fatty Acid (EPA) and Docosahexaenoic Fatty Acids (DHA) Supplementation on the Inflammation State and Metabolic Disorders in Patients With Duchenne Muscular Dystrophy or Becker Muscular Dystrophy

Details for clinical trial NCT01826422

Clinical trial NCT01826422 - References